Quick Answer
Matinas BioPharma Holdings, Inc. reported Research And Development Expense of $85.0 thousand for the year ending 2025.
- Matinas BioPharma Holdings, Inc. showed a decrease of -99.3% in Research And Development Expense from 2024 to 2025.
- This data is from Matinas BioPharma Holdings, Inc.'s annual report (Form 10-K), filed with the SEC on March 31, 2026.
- XBRL data for this metric is available from 2013 to 2025 (13 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Over the full 13 years of available data (2013 to 2025), Matinas BioPharma Holdings, Inc.'s Research And Development Expense has declined by 95.2%.
- Historical annual values: Fiscal year 2025: $85.0 thousand | Fiscal year 2024: $11.43 million | Fiscal year 2023: $14.49 million | Fiscal year 2022: $16.68 million | Fiscal year 2021: $14.58 million | Fiscal year 2020: $14.36 million | Fiscal year 2019: $11.23 million | Fiscal year 2018: $6.79 million | Fiscal year 2017: $9.01 million | Fiscal year 2016: $3.95 million | Fiscal year 2015: $5.29 million | Fiscal year 2014: $5.18 million | Fiscal year 2013: $1.76 million.
- Data sourced from SEC EDGAR public filings as of June 20, 2026.
Last verified: